Current atherosclerosis reports|2025|Saeed Z, Apovian C
Review
PMID: 41410846
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Aims The primary objective of this study is to evaluate the short-term impact of tirzepatide on liver fibrosis markers, specifically the Fibrosis-3 index (FIB-3), Fibrosis-4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI)…